Last updated: February 27, 2026
What is the drug identified by NDC 42571-0274?
The National Drug Code (NDC) 42571-0274 corresponds to Rifampin Capsules, 300 mg. This generic antibiotic is used primarily in the treatment of tuberculosis and other bacterial infections.
Market size and demand dynamics
Global and US market landscape
- The global tuberculosis (TB) drug market was valued at approximately USD 1.2 billion in 2022.
- The US accounts for around 20% of global TB drug sales, with recent estimates indicating a value of USD 250 million.
- There are an estimated 9 million new TB cases globally annually, with the US reporting roughly 9,000 cases in 2021.
- Rifampin is a core component of first-line TB therapy across both developed and developing countries.
Supply and manufacturing
- Rifampin is produced by major pharmaceutical firms, including Pfizer, GSK, and Teva, with generic versions dominating the market.
- Patent status: The original patent expired in the late 1980s; current production relies on generic manufacturing.
Market growth factors
- Increasing TB incidence in low- and middle-income countries sustains demand.
- Rising drug resistance complicates treatment, prompting the development of combination therapies.
- Global initiatives (e.g., WHO End TB Strategy) aim to improve access and treatment adherence.
Key market trends
- Shift toward fixed-dose combination (FDC) products reduces pill burden.
- Accelerated adoption of generic versions increases accessibility but amplifies price competition.
- Governments and NGOs subsidize TB medication costs in low-income regions.
Price analysis and projections
Current pricing landscape
| Region |
Typical Wholesale Price (per 300 mg capsule) |
Retail Price Range (per capsule) |
Notes |
| United States |
USD 2.00 – USD 4.50 |
USD 4.00 – USD 8.00 |
Prices vary by pharmacy and insurance status |
| India |
USD 0.10 – USD 0.50 |
USD 0.20 – USD 1.00 |
Generic availability dominates |
| Europe |
USD 1.50 – USD 3.50 |
USD 3.00 – USD 7.00 |
Pricing controlled by health authorities |
| Africa |
USD 0.05 – USD 0.30 |
USD 0.10 – USD 0.70 |
Prices heavily subsidized |
Pricing trends (past 5 years)
- US prices have increased marginally, driven by supply chain disruptions and regulatory changes.
- Developing markets saw significant price reductions due to increased generic competition.
- No significant patent barriers currently influence pricing.
Forecast for 2024–2028
- In developed markets, wholesale prices are projected to stabilize or slightly decline due to market saturation.
- In emerging markets, prices are expected to fall further, reaching USD 0.05–USD 0.10 per capsule by 2026.
- The US retail price may see a slight increase (~3% annually) due to inflation and operational costs, reaching USD 8–USD 9 per capsule in 2028.
Price factors influences
- Manufacturing costs: Decrease as patent barriers diminish.
- Regulatory environments: Impact pricing through approvals and reimbursement policies.
- Market competition: Surge in generics prohibits price inflation.
- Raw material costs: Prices for rifampin raw materials remain stable but are susceptible to geopolitical factors.
Competitive landscape
- Several manufacturers produce rifampin generics, with top players including Mylan, Sandoz, and Sun Pharmaceutical.
- Limited branded options; most sales are through generics.
- Focus shifts to FDCs and improved formulations rather than price differentiation.
Regulatory and policy impacts
- WHO prequalification and FDA approvals influence import/export capabilities.
- Price controls in Europe and Latin America restrict wholesale and retail pricing.
- US government programs like CDC procurement influence pricing for public health use.
Risks and uncertainties
- Patent litigation or new formulations could alter market dynamics.
- Emergence of rifampin-resistant TB strains may reduce demand.
- Supply chain disruptions, especially during global crises, could temporarily inflate prices.
Key takeaways
- The global rifampin market is well-established, with stable demand driven by TB treatment needs.
- Prices vary significantly across regions, with generic drugs dominating in price-sensitive markets.
- US retail prices are projected to grow modestly, while developing country prices will trend downward.
- Market stability is underpinned by high generic competition and global health initiatives, with limited potential for substantial price hikes.
FAQs
Q1: How does patent status affect rifampin pricing?
A1: Patent expiration opened the market to generics, decreasing prices and increasing competition. Current patent barriers are minimal, facilitating market entry for generics.
Q2: What factors could cause rifampin prices in the US to increase?
A2: Supply shortages, regulatory changes, or increased production costs could raise prices. However, current trends suggest stability with slight growth.
Q3: How do global health policies impact rifampin market dynamics?
A3: Initiatives like WHO's End TB Strategy enhance access, often through subsidies and procurement programs, influencing pricing and availability.
Q4: Is rifampin likely to face reduced demand due to resistance?
A4: Yes, rising rifampin-resistant strains could reduce demand for first-line therapy, but new formulations or combination therapies may offset this trend.
Q5: Which regions represent the largest growth opportunities?
A5: Emerging markets, especially Africa and Southeast Asia, continue to expand due to high TB prevalence and lower current prices.
References
- World Health Organization. (2022). Global tuberculosis report 2022. WHO.
- IQVIA. (2022). Global Market Data on Anti-infectives.
- U.S. Food & Drug Administration. (2022). Approved Drug Products.
- Access to Medicines Foundation. (2022). Antibiotics Market Outlook.
- IMS Health. (2022). Pharmaceutical Pricing Trends Report.
